Baricitinib vs Durvalumab

Baricitinib vs Durvalumab: Overview

This comparison examines the pharmacological differences between Baricitinib and Durvalumab.

Mechanism of Action

Baricitinib: Selective JAK1 and JAK2 inhibitor blocking cytokine signaling involved in inflammation.

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Baricitinib — 12 hours; Durvalumab — 17 days.

Chemical Properties

Molecular Formula: Baricitinib — C16H17N7O2S.

Molecular Weight: Baricitinib — 371.4170 g/mol.

Type: Baricitinib — Small molecule; Durvalumab — Antibody.